Insulet Past Earnings Performance
Past criteria checks 1/6
Insulet has been growing earnings at an average annual rate of 66.2%, while the Medical Equipment industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 20.8% per year. Insulet's return on equity is 16.1%, and it has net margins of 10%.
Key information
66.25%
Earnings growth rate
65.75%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 20.85% |
| Return on equity | 16.14% |
| Net Margin | 10.01% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher
Sep 06
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings
Aug 14Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold
Aug 14Insulet (NASDAQ:PODD) Has A Rock Solid Balance Sheet
Aug 04Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?
Jul 22Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Jun 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
May 28Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26%
May 15We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease
Apr 21Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?
Apr 07Insulet Leans Bullish (Technical Analysis)
Mar 18Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Mar 05Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital
Feb 18Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)
Jan 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
Jan 13Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly
Dec 18Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors
Dec 04Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Nov 20Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?
Nov 20Returns At Insulet (NASDAQ:PODD) Are On The Way Up
Nov 08Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues
Oct 15Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?
Oct 03Is Insulet (NASDAQ:PODD) A Risky Investment?
Sep 09Insulet: Turning More Constructive, Valuations Still Stretched
Sep 05
Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks
Expansion into new international markets and integration with leading diabetes sensors position Insulet for increased global penetration and competitive advantage.Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Jun 11Insulet: Insulating Patients, Investors Still Have To Wait
Mar 28Revenue & Expenses Breakdown
How Insulet makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 2,360 | 236 | 1,013 | 249 |
| 31 Mar 25 | 2,199 | 402 | 978 | 229 |
| 31 Dec 24 | 2,072 | 418 | 917 | 220 |
| 30 Sep 24 | 1,984 | 421 | 869 | 201 |
| 30 Jun 24 | 1,873 | 395 | 816 | 204 |
| 31 Mar 24 | 1,781 | 234 | 772 | 205 |
| 31 Dec 23 | 1,697 | 206 | 735 | 205 |
| 30 Sep 23 | 1,557 | 120 | 694 | 213 |
| 30 Jun 23 | 1,465 | 63 | 653 | 200 |
| 31 Mar 23 | 1,368 | 1 | 622 | 187 |
| 31 Dec 22 | 1,305 | 5 | 568 | 180 |
| 30 Sep 22 | 1,243 | 17 | 538 | 173 |
| 30 Jun 22 | 1,178 | 35 | 515 | 165 |
| 31 Mar 22 | 1,142 | 45 | 484 | 163 |
| 31 Dec 21 | 1,099 | 17 | 466 | 160 |
| 30 Sep 21 | 1,037 | -29 | 474 | 157 |
| 30 Jun 21 | 996 | -30 | 446 | 158 |
| 31 Mar 21 | 959 | 9 | 411 | 152 |
| 31 Dec 20 | 904 | 7 | 384 | 147 |
| 30 Sep 20 | 868 | 29 | 334 | 144 |
| 30 Jun 20 | 826 | 18 | 320 | 137 |
| 31 Mar 20 | 777 | 5 | 315 | 135 |
| 31 Dec 19 | 738 | 12 | 298 | 132 |
| 30 Sep 19 | 694 | 17 | 270 | 126 |
| 30 Jun 19 | 653 | 17 | 268 | 117 |
| 31 Mar 19 | 600 | 14 | 251 | 103 |
| 31 Dec 18 | 564 | 3 | 248 | 95 |
| 30 Sep 18 | 529 | -13 | 249 | 80 |
| 30 Jun 18 | 500 | -17 | 227 | 78 |
| 31 Mar 18 | 486 | -23 | 218 | 77 |
| 31 Dec 17 | 464 | -27 | 209 | 76 |
| 30 Sep 17 | 437 | -29 | 191 | 72 |
| 30 Jun 17 | 410 | -30 | 179 | 65 |
| 31 Mar 17 | 387 | -26 | 168 | 60 |
| 31 Dec 16 | 367 | -27 | 166 | 56 |
| 30 Sep 16 | 347 | -34 | 159 | 53 |
| 30 Jun 16 | 324 | -49 | 156 | 49 |
| 31 Mar 16 | 297 | -62 | 149 | 48 |
| 31 Dec 15 | 264 | -62 | 139 | 43 |
| 30 Sep 15 | 253 | -51 | 129 | 38 |
| 30 Jun 15 | 256 | -44 | 126 | 35 |
| 31 Mar 15 | 268 | -56 | 128 | 29 |
| 31 Dec 14 | 231 | -48 | 108 | 28 |
| 30 Sep 14 | 285 | -49 | 112 | 27 |
Quality Earnings: PODD has a large one-off loss of $117.0M impacting its last 12 months of financial results to 30th June, 2025.
Growing Profit Margin: PODD's current net profit margins (10%) are lower than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PODD's earnings have grown significantly by 66.2% per year over the past 5 years.
Accelerating Growth: PODD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PODD had negative earnings growth (-40.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.6%).
Return on Equity
High ROE: PODD's Return on Equity (16.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 02:49 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insulet Corporation is covered by 62 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anand Vankawala | Avondale Partners |
| null null | Baird |
| Jeffrey Johnson | Baird |